Evercore ISI began coverage on shares of Bruker (NASDAQ:BRKR) in a note issued to investors on Wednesday, The Fly reports. The firm set a $36.00 price target on the medical research company’s stock. Evercore ISI’s target price would suggest a potential upside of 3.42% from the stock’s current price.
Several other equities research analysts also recently commented on BRKR. Zacks Investment Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Cowen reissued a “hold” rating and set a $35.00 target price on shares of Bruker in a research report on Thursday, December 21st. Morgan Stanley reissued an “equal weight” rating and set a $35.00 target price on shares of Bruker in a research report on Thursday, December 14th. Citigroup boosted their target price on shares of Bruker from $29.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, Bank of America raised shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price for the company in a research report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $31.42.
Bruker (BRKR) traded up $0.29 during mid-day trading on Wednesday, reaching $34.81. 348,575 shares of the company traded hands, compared to its average volume of 330,750. The firm has a market capitalization of $5,338.91, a price-to-earnings ratio of 37.03, a price-to-earnings-growth ratio of 2.58 and a beta of 1.12. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65. Bruker has a 1-year low of $21.24 and a 1-year high of $36.53.
Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Bruker by 3.0% during the 2nd quarter. BlackRock Inc. now owns 4,747,514 shares of the medical research company’s stock worth $136,918,000 after acquiring an additional 139,792 shares during the period. AJO LP bought a new stake in Bruker during the 2nd quarter worth approximately $46,075,000. State Street Corp increased its holdings in Bruker by 0.5% during the 2nd quarter. State Street Corp now owns 1,407,941 shares of the medical research company’s stock worth $40,605,000 after acquiring an additional 7,356 shares during the period. Dimensional Fund Advisors LP increased its holdings in Bruker by 1.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 921,431 shares of the medical research company’s stock worth $27,412,000 after acquiring an additional 11,466 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of Bruker by 4.7% in the 3rd quarter. Wells Fargo & Company MN now owns 845,373 shares of the medical research company’s stock worth $25,150,000 after buying an additional 37,858 shares during the last quarter. Institutional investors own 65.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking and Market News and is the property of of American Banking and Market News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/03/bruker-brkr-receives-new-coverage-from-analysts-at-evercore-isi.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
